科兴制药拟发H股 A股募11亿控股股东近俩月套现4.4亿

Group 1 - The company, Sinovac Biotech, is planning to issue overseas listed shares (H-shares) and list on the Hong Kong Stock Exchange to enhance its international business development and competitiveness [1] - The H-share listing requires approval from the company's board, shareholders, and various regulatory bodies, indicating uncertainty in the process [1] - The company aims to leverage international capital market resources to optimize its capital structure and diversify financing channels [1] Group 2 - Sinovac Biotech's major shareholder, Shenzhen Keyi Pharmaceutical Holdings, plans to transfer 6,037,717 shares, representing 3.00% of the total share capital, due to funding needs [2] - The transfer price is set at 36.70 yuan per share, totaling approximately 221.58 million yuan [2] - Following the transfer, the shareholding of Keyi Pharmaceutical and its associated parties will decrease from 63.89% to 60.38% [2] Group 3 - Keyi Pharmaceutical previously reduced its holdings by 5,989,200 shares, or 3.00% of the total share capital, between June 26 and July 9, 2025, with a total amount of approximately 220.99 million yuan [3] - Over the past two months, Sinovac Biotech has realized approximately 443 million yuan from these transactions [4] - The company was listed on the Shanghai Stock Exchange on December 14, 2020, raising a total of 1.11 billion yuan, with a net amount of 999.5 million yuan after expenses [4][5]